Incyte Corporation
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
Phone: (855) 446-2983Website: https://www.incyte.com/Careers: www.incyte.com/join-us/join-incyte.aspxPatient Assistance Program: www.incytecares.com
Latest news
- Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
18 June 2025 - Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
15 May 2025 - FDA Approves Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
22 March 2023 - Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
20 December 2022 - Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
26 August 2022 - Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo
18 July 2022 - Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
22 September 2021 - FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)
21 September 2021 - Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
23 July 2021 - Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
11 June 2021
Drugs Associated with Incyte Corporation
Incyte Corporation manufactures, markets and/or distributes more than 9 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Iclusig
Generic name: ponatinib Drug class: BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors |
2 reviews | 3.0 / 10 |
|
Jakafi
Generic name: ruxolitinib Drug class: multikinase inhibitors |
33 reviews | 7.5 / 10 |
|
Monjuvi
Generic name: tafasitamab Drug class: CD19 monoclonal antibodies |
1 review | 5.0 / 10 |
|
Niktimvo
Generic name: axatilimab Drug class: miscellaneous antineoplastics |
||
|
Olumiant
Generic name: baricitinib Drug class: antirheumatics, selective immunosuppressants |
15 reviews | 8.2 / 10 |
|
Opzelura
Generic name: ruxolitinib Drug class: topical antineoplastics |
4 reviews | 9.3 / 10 |
|
Pemazyre
Generic name: pemigatinib Drug class: multikinase inhibitors |
1 review | 1.0 / 10 |
|
Tabrecta
Generic name: capmatinib Drug class: multikinase inhibitors |
1 review | 8.0 / 10 |
|
Zynyz
Generic name: retifanlimab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||